DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
13 hedge funds and large institutions have $12.9M invested in DMK Pharmaceuticals Corporation Common Stock in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
+$3.29M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.55M |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$1.07M |
| 4 |
SM
Scoggin Management
New York
|
+$939K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$783K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWMDMG
1
Austin W. Marxe & David M. Greenhouse
New York
| $3.35M | +$3.29M | +7,500 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.6M | +$2.55M | +5,815 | New |
|
|
GP
3
Grow Partners
San Diego,
California
| $2.08M | +$2.04M | +4,643 | New |
|
|
GPCM
4
Granite Point Capital Management
Boston,
Massachusetts
| $1.31M | +$1.28M | +2,929 | New |
|
|
BA
5
Bard Associates
Chicago,
Illinois
| $1.09M | +$1.07M | +2,442 | New |
|
|
SM
6
Scoggin Management
New York
| $959K | +$939K | +2,143 | New |
|
|
DCM
7
DAFNA Capital Management
Los Angeles,
California
| $799K | +$783K | +1,786 | New |
|
|
PCM
8
Prelude Capital Management
New York
| $288K | +$282K | +643 | New |
|
|
SC
9
Sophrosyne Capital
New York
| $267K | +$263K | +600 | New |
|
|
EEG
10
E.E. Geduld
| $160K | +$156K | +357 | New |
|
11
Morgan Stanley
New York
| $15K | +$14.9K | +34 | New |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $1K | +$1.31K | +3 | New |
|
13
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$438 | +1 | New |
|
DMK Hedge Fund Activity: Q4 2013 in Review
13 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2013, worth a combined $12.9M.
Buyers outnumbered sellers: 13 funds opened new DMK positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Austin W. Marxe & David M. Greenhouse, opening a new position worth an estimated $3.29M.
- 13 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $12.9M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2013.
- 13 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2013 and 0 closed out, a net change of +13 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2013 was Austin W. Marxe & David M. Greenhouse, an estimated $3.29M added.
Based on aggregated 13F filings for Q4 2013.